Contributions
Abstract: EP1827
Type: ePoster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Background: In patients with multiple sclerosis (PwMS), there is an evidence that Fampyra LR improves walking and also the performance of activities of daily living (ADL). Consequently, we investigated the respondence of Fampyra LR in terms of performance and satisfaction of meaningful and self-chosen ADLs by using the Canadian Occupational Performance Measure (COPM).
Method: There were 111 consecutive PwMS who were referred by neurologists to Occupational therapy (OT). They were candidates for treatment with Fampyra LR, and were independently followed within OT. PwMS were assessed by the COPM before starting treatment with Fampira LR and reassessed after two weeks. COPM (Law et al, 1991) is standardized and well-validated semi-structured interview. It assesses patients´ perception and satisfaction of purposeful, meaningful and self-chosen ADLs. It is therefore patient-centred assessment. As part of the interview process, patients are asked to score their current level of performance and satisfaction with their performance of ADLs. Scores are within the range from 1-10 ; 1 relates to great difficulty or not satisfied and 10 to no difficulties or completely satisfied. SPSS was used for analysis.
Results: In total, 106 PwMS completed the study; there were 30 male / 81 female, average age was 51±11 years and average EDSS was 5.5±1.1. The average initial COPM performance score was 4.6 ± 2.2 and the average reassessment score was 6.2± 2.3. This difference was significantly important (p< 0,001). The average initial COPM satisfaction score was 5.1± 2.3 and the average reassessment score was 6.6±2.5. This difference was significantly important (p< 0,001).
Conclusion: The ADL performance, measured in terms of PwMS´ perception and satisfaction with their performance of meaningful and self-chosen ADLs has improved after Fampyra LR treatment. Further relation of this improvement with walking changes could additionally clarify this topic.
Disclosure: Jelka Jansa has nothing to disclose.
Zorana Sicherl has nothing to disclose.
Simona Martić has nothing to disclose.
Katja Angleitner has nothing to disclose.
Rok Koritnik has nothing to disclose.
Alenka Horvat Ledinek has nothing to disclose.
Uroš Rot has nothing to disclose.
Sasa Sega has nothing to disclose.
Abstract: EP1827
Type: ePoster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Background: In patients with multiple sclerosis (PwMS), there is an evidence that Fampyra LR improves walking and also the performance of activities of daily living (ADL). Consequently, we investigated the respondence of Fampyra LR in terms of performance and satisfaction of meaningful and self-chosen ADLs by using the Canadian Occupational Performance Measure (COPM).
Method: There were 111 consecutive PwMS who were referred by neurologists to Occupational therapy (OT). They were candidates for treatment with Fampyra LR, and were independently followed within OT. PwMS were assessed by the COPM before starting treatment with Fampira LR and reassessed after two weeks. COPM (Law et al, 1991) is standardized and well-validated semi-structured interview. It assesses patients´ perception and satisfaction of purposeful, meaningful and self-chosen ADLs. It is therefore patient-centred assessment. As part of the interview process, patients are asked to score their current level of performance and satisfaction with their performance of ADLs. Scores are within the range from 1-10 ; 1 relates to great difficulty or not satisfied and 10 to no difficulties or completely satisfied. SPSS was used for analysis.
Results: In total, 106 PwMS completed the study; there were 30 male / 81 female, average age was 51±11 years and average EDSS was 5.5±1.1. The average initial COPM performance score was 4.6 ± 2.2 and the average reassessment score was 6.2± 2.3. This difference was significantly important (p< 0,001). The average initial COPM satisfaction score was 5.1± 2.3 and the average reassessment score was 6.6±2.5. This difference was significantly important (p< 0,001).
Conclusion: The ADL performance, measured in terms of PwMS´ perception and satisfaction with their performance of meaningful and self-chosen ADLs has improved after Fampyra LR treatment. Further relation of this improvement with walking changes could additionally clarify this topic.
Disclosure: Jelka Jansa has nothing to disclose.
Zorana Sicherl has nothing to disclose.
Simona Martić has nothing to disclose.
Katja Angleitner has nothing to disclose.
Rok Koritnik has nothing to disclose.
Alenka Horvat Ledinek has nothing to disclose.
Uroš Rot has nothing to disclose.
Sasa Sega has nothing to disclose.